.Pharmacolibrary.Drugs.ATC.R.R03DX10 .Pharmacolibrary.Drugs.ATC.R.R03DX10| name: | Benralizumab | |
| ATC code: | R03DX10 | route: | subcutaneous |
| compartments: | 2 | |
| dosage: | 30 | mg |
| volume of distribution: | 3.09 | L |
| clearance: | 0.29 | L/day |
| other parameters in model implementation | ||
Benralizumab is a humanized monoclonal antibody targeting the interleukin-5 receptor alpha (IL-5RĪ±) on eosinophils, leading to their depletion. It is used for the treatment of severe eosinophilic asthma and is approved for this indication in many countries.
Population pharmacokinetics in adults and adolescents (12ā75 years) with severe eosinophilic asthma following subcutaneous administration.
Wang, B, et al., & Roskos, LK (2017). Population Pharmacokinetics and Pharmacodynamics of Benralizumab in Healthy Volunteers and Patients With Asthma. CPT: pharmacometrics & systems pharmacology 6(4) 249ā257. DOI:10.1002/psp4.12160 PUBMED:https://pubmed.ncbi.nlm.nih.gov/28109128
Yan, L, et al., & Roskos, LK (2019). Population Pharmacokinetic Modeling of Benralizumab in Adult and Adolescent Patients with Asthma. Clinical pharmacokinetics 58(7) 943ā958. DOI:10.1007/s40262-019-00738-4 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30854591